Home >> Research Area >>Neuroscience>>AChR>> Rocuronium Bromide

Rocuronium Bromide

TGF-βR I kinase inhibitor CAS# 119302-91-9

Rocuronium Bromide

Catalog No. BCC1068----Order now to get a substantial discount!

Product Name & Size Price Stock
Rocuronium Bromide: 5mg $12 In Stock
Rocuronium Bromide: 10mg Please Inquire In Stock
Rocuronium Bromide: 20mg Please Inquire Please Inquire
Rocuronium Bromide: 50mg Please Inquire Please Inquire
Rocuronium Bromide: 100mg Please Inquire Please Inquire
Rocuronium Bromide: 200mg Please Inquire Please Inquire
Rocuronium Bromide: 500mg Please Inquire Please Inquire
Rocuronium Bromide: 1000mg Please Inquire Please Inquire
Related Products
  • A-867744

    Catalog No.:BCC1324
    CAS No.:1000279-69-5
  • Rivastigmine

    Catalog No.:BCC1900
    CAS No.:123441-03-2
  • Rocuronium

    Catalog No.:BCC1906
    CAS No.:143558-00-3

Quality Control of Rocuronium Bromide

Number of papers citing our products

Chemical structure

Rocuronium Bromide

3D structure

Chemical Properties of Rocuronium Bromide

Cas No. 119302-91-9 SDF Download SDF
PubChem ID 441351 Appearance Powder
Formula C32H53BrN2O4 M.Wt 609.68
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 155 mg/mL (254.23 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate;bromide
SMILES CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-]
Standard InChIKey OYTJKRAYGYRUJK-FMCCZJBLSA-M
Standard InChI InChI=1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Rocuronium Bromide

DescriptionRocuronium Bromide is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal musclerelaxation during surgery or mechanical ventilation. IC50 Value: in vitro: Rocuronium reduced the indirectly elicited twitch tensions in normal (50% inhibitory concentration [IC(50)], 9.84 [9.64-10.04] μM, mean [95% confidence interval]) and all pretreated diaphragms (P < .01, n = 6) in a concentration-dependent fashion [1]. The ED95 of rocuronium is essentially the same for children as for adults. Its duration of action is similar to vecuronium, and it is shorter for children than for adults. Rocuronium is readily reversed with conventional doses of cholinesterase-inhibiting drugs [2]. Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively [3]. in vivo: Only 8.7 +/- 5.7% (SD) and 6.0 +/- 2.8% of an injected dose of ORG 9426 and ORG 9616 was excreted into the urine, respectively. Conversely, 54.4 +/- 9.2% and 52.4 +/- 9.2% of an injected dose of ORG 9426 and 35.7 +/- 12.2% and 46.8 +/- 9.7% of ORG 9616 were excreted into the bile in cats without and with renal pedicle ligation, respectively [4].

References:
[1]. Narimatsu E, Niiya T, Takahashi K, Pralidoxime inhibits paraoxon-induced depression of rocuronium-neuromuscular block in a time-dependentfashion. Am J Emerg Med. 2012 Jul;30(6):901-7. [2]. Wicks TC. The pharmacology of rocuronium bromide (ORG 9426). AANA J. 1994 Feb;62(1):33-8. [3]. Wierda JM, Kleef UW, Lambalk LM, The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth. 1991 May;38(4 Pt 1):430-5. [4]. Khuenl-Brady K, Castagnoli KP, Canfell PC, The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. Anesthesiology. 1990 Apr;72(4):669-74.

Rocuronium Bromide Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Rocuronium Bromide Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Rocuronium Bromide

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.6402 mL 8.201 mL 16.402 mL 32.8041 mL 41.0051 mL
5 mM 0.328 mL 1.6402 mL 3.2804 mL 6.5608 mL 8.201 mL
10 mM 0.164 mL 0.8201 mL 1.6402 mL 3.2804 mL 4.1005 mL
50 mM 0.0328 mL 0.164 mL 0.328 mL 0.6561 mL 0.8201 mL
100 mM 0.0164 mL 0.082 mL 0.164 mL 0.328 mL 0.4101 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Rocuronium Bromide

Rocuronium Bromide is an aminosteroid non-depolarizing neuromuscular blocker.

Featured Products
New Products
 

References on Rocuronium Bromide

Pharmacodynamic comparison of rocuronium bromide between patients from the plateau area and from the plain area.[Pubmed:27339667]

J Evid Based Med. 2016 Aug;9(3):112-115.

OBJECTIVES: We aimed to conduct a pharmacodynamic comparison of Rocuronium Bromide between patients from the plateau area and from the plain area. METHODS: A total of 104 patients who received laparoscopic cholecystectomy in Sichuan Provincial People's Hospital and Aba Autonomous Prefecture People's Hospital from October 2015 to December 2015 were included in this study. Among them, 46 patients were from the plateau area and 58 were from the plain area. Both groups received total intravenous anesthesia (TIVA) with a dose of 0.6 mg/kg Rocuronium Bromide during induction. In the meantime, neuromuscular block was monitored using a train-of-four (TOF) stimulation mode. The onset time (time to achieve the lowest TOF value after the injection of Rocuronium Bromide), duration of maximal neuromuscular block (duration of lowest T1 value), time to 25% recovery, time to 75% recovery, recovery index (time from 25% recovery to 75% recovery), time to extubation, length of stay in Post Anesthesia Care Unit (PACU) and muscle strength upon PACU discharge were all recorded. RESULTS: The onset time, time to 25% recovery, time to 75% recovery and time to extubation were all significantly prolonged in patients from the plateau area after receiving one single dose of Rocuronium Bromide (P < 0.05). However, both groups didn't show any significant difference in maximal neuromuscular block, recovery index (time from 25% recovery to 75% recovery), length of stay in PACU, or muscle strength upon PACU discharge (P > 0.05). CONCLUSIONS: Compared to patients from the plain area, patients from the plateau area showed prolonged onset time of Rocuronium Bromide, reduced metabolic capabilities, and longer duration of muscular relaxation.

Rocuronium Bromide Inhibits Inflammation and Pain by Suppressing Nitric Oxide Production and Enhancing Prostaglandin E2 Synthesis in Endothelial Cells.[Pubmed:28043117]

Int Neurourol J. 2016 Dec;20(4):296-303.

PURPOSE: Rocuronium Bromide is a nondepolarizing neuromuscular blocking drug and has been used as an adjunct for relaxation or paralysis of the skeletal muscles, facilitation of endotracheal intubation, and improving surgical conditions during general anesthesia. However, intravenous injection of Rocuronium Bromide induces injection pain or withdrawal movement. The exact mechanism of Rocuronium Bromide-induced injection pain or withdrawal movement is not yet understood. We investigated whether Rocuronium Bromide treatment is involved in the induction of inflammation and pain in vascular endothelial cells. METHODS: For this study, calf pulmonary artery endothelial (CPAE) cells were used, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, Western blot, nitric oxide detection, and prostaglandin E2 immunoassay were conducted. RESULTS: Rocuronium Bromide treatment inhibited endothelial nitric oxide synthase and suppressed nitric oxide production in CPAE cells. Rocuronium Bromide activated cyclooxygenase-2, inducible nitric oxide synthase and increased prostaglandin E2 synthesis in CPAE cells. CONCLUSIONS: Rocuronium Bromide induced inflammation and pain in CPAE cells. Suppressing nitric oxide production and enhancing prostaglandin E2 synthesis might be associated with Rocuronium Bromide-induced injection pain or withdrawal movement.

Ease of intubation: A randomized, double-blind study to compare two doses of rocuronium bromide for endotracheal intubation.[Pubmed:27746543]

Anesth Essays Res. 2016 Sep-Dec;10(3):512-515.

CONTEXT: Clinical need for a nondepolarizing agent with a rapid onset time and a brief duration of action has led to the development of Rocuronium Bromide. AIMS: The aim of this study was to evaluate optimal dose of Rocuronium Bromide for intubation and to compare the onset time, duration of action, intubating conditions, and hemodynamic effects of two doses of Rocuronium Bromide. SETTINGS AND DESIGN: A prospective, randomized, double-blind study. MATERIALS AND METHODS: All the patients were divided in a randomized, double-blind fashion into two groups of twenty patients each. Group I patients received Rocuronium Bromide 0.6 mg/kg intravenously and intubated at 60 s, Group II patients received Rocuronium Bromide 0.9 mg/kg and intubated at 60 s. The neuromuscular block was assessed using single twitch stimulation of 0.1 Hz at adductor pollicis muscle of hand at every 10 s. STATISTICAL ANALYSIS USED: The results were compiled and analyzed statistically using Chi-square test for qualitative data and Student's t-test for quantitative data. RESULTS: Time of onset was significantly shorter (P < 0.01) and duration of action was prolonged (P < 0.001) for Group II as compared to Group I. The intubating conditions were (excellent + good) in 100% patients of Group II and (excellent + good) in 80% of Group I. There was no significant change in pulse rate and mean arterial pressure from the baseline value after the administration of muscle relaxants in either of the two groups. CONCLUSIONS: Rocuronium Bromide 0.9 mg/kg is a safer alternative to Rocuronium Bromide 0.6 mg/kg for endotracheal intubation with shorter time of onset and better intubating conditions.

Description

Rocuronium Bromide (ORG 9426 Bromide) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal musclerelaxation during surgery or mechanical ventilation.

Keywords:

Rocuronium Bromide,119302-91-9,Natural Products,AChR, buy Rocuronium Bromide , Rocuronium Bromide supplier , purchase Rocuronium Bromide , Rocuronium Bromide cost , Rocuronium Bromide manufacturer , order Rocuronium Bromide , high purity Rocuronium Bromide

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: